



Extension of Maturity Date of Convertible Notes

NEW YORK and SYDNEY, Australia, November 22, 2021 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that the maturity dates of the two convertible notes issued in May 2020 have been extended to May 2022.

As an incentive to extend the maturity dates, the Company has agreed to issue 5% more shares to the noteholders upon conversion. Based on the new terms, the maximum number of shares to be issued is 1,806,025 shares. All other terms of the convertible notes remain unchanged.

For details of the convertible notes, please refer to our announcement dated 27 May 2020.

-###-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

For further information, please contact us at:

Phone: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com